1
Thomas R Tice, Jay K Staas, Teresa M Ferrell: Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol. Southern Research Institute, Barbara Rae Venter, Jennifer Wahlston, Rae Venter Law Group P C, October 23, 2001: US06306425 (54 worldwide citation)

An injectable slow-release naltrexone formulation is provided comprising naltrexone in a poly(D,L-lactide) matrix with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, naltrexone is released in a controlled manner over an extended period of time. The composi ...


2
Thomas R Tice, Jay K Staas, Teresa M Ferrell, Peter Markland: Injectable opioid partial agonist or opioid antagonist microparticle compositions and their use in reducing consumption of abused substances. Southern Research Institute, Barbara Rae Venter, Rae Venter Law Group P C, December 17, 2002: US06495155 (46 worldwide citation)

An injectable slow-release partial opioid agonist or opioid antagonist formulation is provided comprising a partial opioid agonist or opioid antagonist in a poly(D,L-lactide) excipient with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, a partial opioid ag ...


3
Thomas R Tice, Jay K Staas, Teresa M Ferrell, Peter Markland: Injectable methadone, methadone and naltrexone, or buprenorphine and naltrexone microparticle compositions and their use in reducing consumption of abused substances. Brookwood Pharmaceuticals, Fish & Richardson P C, January 6, 2009: US07473431 (4 worldwide citation)

An injectable slow-release methadone, partial opioid agonist or opioid antagonist formulation is provided comprising methadone, a partial opioid agonist or opioid antagonist in a poly(D,L-lactide) excipient with a small amount of residual ethyl acetate. Upon intramuscular or subcutaneous injection o ...


4
Thomas R Tice, Jay K Staas, Teresa M Ferrell, Peter Markland: Injectable opioid partial agonist or opioid antagonist microparticle compositions and their use in reducing consumption of abused substances. Southern Research, Barbara Rae Venter PhD, Rae Venter Law Group PC, August 14, 2003: US20030152638-A1

An injectable slow-release partial opioid agonist or opioid antagonist formulation is provided comprising a partial opioid agonist or opioid antagonist in a poly(D,L-lactide) excipient with a small amount of residual ethyl acetate. Upon intramuscular injection of the composition, a partial opioid ag ...


5

6